Epitan raises A$10 million from private placement of stock

By Sheri Kasprzak

New York, Nov. 28 - Epitan Ltd. said it has received A$10 million from a private placement of stock.

Absolute Capital Management agreed to buy A$10 million in stock with warrants from the company.

The terms of the deal could not be determined by press time Monday.

Proceeds will be used for a phase 2 clinical trial on EPT1647.

Based in Melbourne, Australia, Epitan is a pharmaceutical company focused on dermatological products.

On Monday, the company's stock closed unchanged at A$0.345.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.